For many years, Davis Polk has been advising clients – ranging from the world’s largest healthcare companies to startups – with a focus on pharmaceuticals, biotechnology, diagnostics, medical devices and healthcare equipment, genetics, and other areas.
We have consistently helped our clients achieve their strategic objectives in a wide variety of transactions through ever-changing market and regulatory conditions. Through our broad transactional experience, we understand the complex issues that pharmaceutical and biotechnology companies face in acquisitions, financings, divestitures, joint ventures, partnerships, strategic alliances, licensing arrangements, collaborations, distribution agreements, internal investigations and litigation.
Our pharmaceutical and biotechnology clients also benefit from our related practices across a number of disciplines, including antitrust and competition, intellectual property, FCPA/U.K. Bribery Act advice, tax and executive compensation.
We have advised on some of the industry's most high-profile transactions. View our recent experience in: